

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8707

Ravi V.J. CHARI, et al.

Appln. No.: Unassigned

Divisional of U.S. Appln. No. 10/410,143

Group Art Unit: 1624 (Parent)

Confirmation No.: Not yet assigned

Examiner: Not yet assigned

Filed: January 16, 2004

For: **PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-
CONTAINING MAYTANSINOIDS**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which are all the references of record in parent application No. 10/410,143. Applicant is not submitting duplicate copies of these references but requests that they be listed on the face of any patent granted on the above application. (See 37 CFR §1.98(d)). Copies of any cited copending applications, if not previously submitted, are being submitted herewith.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not

Information Disclosure Statement
Divisional of U.S. Appln. No. 10/410,143

Attorney Docket No.: A8707

waive any right to take any action that would be appropriate to antedate or otherwise remove any
listed document as a competent reference against the claims of the present application.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: January 16, 2004

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	Unassigned, Divisional of U.S. Appln. No.: 10/410,143
				Confirmation Number	Not yet assigned
				Filing Date	January 16, 2004
				First Named Inventor	Ravi V.J. CHARI
				Art Unit	1624 (Parent)
				Examiner Name	Not yet assigned
				Attorney Docket Number	A8707
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2002/0156274	A1	10/24/2002	Gerald J. Terfloth
		US 4,151,042		04/24/1979	Higashide, et al.
		US 4,331,598		05/25/1982	Hasegawa, et al.
		US 4,424,219		01/03/1984	Naoto HASHIMOTO, et al.
		US 5,208,020		05/04/1993	Ravi J. CHARI, et al.
		US 5,416,064		05/16/1995	Ravi J. CHARI, et al.
		US 6,333,410	B1	12/25/2001	Chari, et al.
		US 6,441,163	B1	08/27/2002	Chari et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		CA	2006408		06/27/1990	Takeda Chemical Industries, Ltd.	
		DE	27 46 253	A1	10/05/1978	Takeda Chemical Industries, Ltd.	Abstract
		DE	2241418	A1	03/07/1974	(inventor/S.M. Kupchan)	Abstract
		EP	26338	A1	04/08/1981	Takeda Chemical Industries, Ltd.	Abstract
		JP	55029972	A2	03/03/1980	Takeda Chemical Industries, Ltd.	Abstract
		JP	53124692	A2	10/31/1978	Takeda Chemical Industries, Ltd.	Abstract
		WO	2001095943	A2	12/20/2000	Corixa Corporation	Abstract
		WO	2001068142	A1	09/20/2001	KTB Tumorforschungsgesellschaft m.b.H.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		ABBOTT B. HUANG, et al., "Maytansine Inhibits Nucleotide Binding at the Exchangeable Site of Tubulin," <i>Biochem. Biophys. Res. Commun.</i> (1985), 128:(3), pp. 1239-46.	Abstract
		AKIYOSHI KAWAI, "Chemical Modification of Ansamitocins. I. Synthesis and Properties of 4,5-deoxymaytansinoids," <i>Chem. Pharm. Bull.</i> 1984, 32:(6), pp. 2194-9.	Abstract
		AKIYOSHI KAWAI, et al., "Chemical Modification of Ansamitocins. III. Synthesis and Biological Effects of 3-Acyl Esters of Maytansinol," <i>Chem. Pharm. Bull.</i> 1984, 32:(9), pp. 3441-51.	
		GUENTER ADAM, "Biologically Active Natural Products as Synthetic Models in Active Substance Development," <i>Z. Chem.</i> , 1981, 21:(8), pp. 273-81.	Abstract
		MASAYUKI SHIMAGAKI, "2-Halovinyl Aryl Sulfones: New Coupling Reagents for Cboxamide Formation," <i>Phosphorus Sulfur</i> , 1983, 16:(1-2), pp. 45-48.	Abstract
		MetaChem Technologies, Inc., <i>Liquid Chromatography, HPLC, IC, CE Column Guide</i> , pp. 53-4 (2000/2001).	
		S. MORRIS KUPCHAN, et al., "Structural Requirements for Antileukemic Activity among the Naturally Occurring and Semisynthetic Maytansinoids," <i>Journal of Medicinal Chemistry</i> , 1978, 21:(1), pp. 31-7.	
		TROELS SKRYDSTRUP, "The Opening of Trans-2,3-epoxy-1-butanol Derivatives with Organometallic Reagents," <i>Tetrahedron Lett.</i> , 1990, 31:(49), pp. 7145-8.	Abstract
		XUEGIN GU, "Studies on the Total Syntheses of Maytansinoids. (III). Synthesis of C5-N Fragment," <i>Sci. Sin., Ser. B (Engl. Ed.)</i> , 1998, 31:(11), pp. 1333-41.	Abstract

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.